Shilpa Medicare launches Lenvatinib Capsules in India under the brand name Lenshil
The company is already marketing the 4 mg and 10 mg strengths
The company is already marketing the 4 mg and 10 mg strengths
This is the second US FDA GMP inspection of this facility within one year
The company will be submitting the responses to US FDA observations within stipulated timeline
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited and its agreed parties
The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
Subscribe To Our Newsletter & Stay Updated